Creutzfeldt-Jakob Disease (CJD)

Overview

Creutzfeldt-Jakob disease (CJD) is the most common human prion disease, occurring at an incidence of approximately 1–2 cases per million people per year worldwide. It belongs to the family of transmissible spongiform encephalopathies (TSEs) — fatal neurodegenerative conditions characterized by the accumulation of a misfolded, protease-resistant form of the prion protein (PrP). CJD is uniformly fatal, typically causing death within months of symptom onset in its most prevalent sporadic form.

Prion Biology and Pathophysiology

The prion protein (PrP) is encoded by the PRNP gene on chromosome 20 and is normally expressed as a GPI-anchored glycoprotein on the cell surface (PrP^C^). In CJD, PrP^C^ undergoes a conformational change — acquiring a β-sheet-rich secondary structure — to form the pathological isoform PrP^Sc^. PrP^Sc^ is both protease-resistant and self-propagating: it templates the conversion of native PrP^C^ molecules into additional PrP^Sc^, creating a self-amplifying cycle of misfolding that spreads through the brain. ^{1Prion protein amplification techniques.2018 · Handbook of clinical neurology · PMID 29887145Open reference}

The accumulation of PrP^Sc^ leads to the hallmark neuropathological features of CJD: spongiform vacuolation (sponge-like holes in the neuropil), neuronal loss, reactive astrogliosis, and microglial activation. These changes are most prominent in the cerebral cortex, basal ganglia, and cerebellum, accounting for the characteristic clinical syndrome. Differential glial vulnerability is well documented — astrocytes and oligodendrocytes show distinct patterns of degeneration across CJD subtypes. ^{2Differential astrocyte and oligodendrocyte vulnerability in murine Creutzfeldt-Jakob disease.2021 · Prion · PMID 34225562Open reference}

Clinical Variants

CJD occurs in four forms:

Sporadic CJD (sCJD) accounts for approximately 85% of cases. It typically affects adults over 60 years and presents with a rapidly progressive dementia accompanied by cerebellar ataxia, myoclonus, visual disturbances, and pyramidal/extrapyramidal signs. Median survival from symptom onset is 4–6 months. No infectious cause is identified; the disease arises from spontaneous PRNP misfolding. ^{3Creutzfeldt-Jakob disease: A comprehensive review of current understanding and research.2024 · Journal of the neurological sciences · PMID 39546829Open reference}

Genetic (familial) CJD (gCJD) represents 10–15% of cases and results from inherited PRNP mutations (e.g., E200K, V210I, D178N). Gerstmann-Sträussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI) are related hereditary prion diseases with distinct phenotypes driven by specific mutations.

Iatrogenic CJD (iCJD) arises from medical procedures transmitting prion-contaminated material, including cadaveric dura mater grafts, pituitary-derived growth hormone, and contaminated neurosurgical instruments. Strict sterilization protocols have dramatically reduced incidence.

Variant CJD (vCJD) emerged in the 1990s linked to consumption of bovine spongiform encephalopathy (BSE)-contaminated beef products. It affects younger individuals (median age ~29 years), presents with prominent psychiatric and sensory prodrome, and has a longer clinical course than sCJD. The neuropathology shows characteristic “florid” amyloid plaques.

Diagnosis

The PRNP codon 129 polymorphism (Met/Val) profoundly influences CJD susceptibility and phenotype — methionine homozygosity (MM) is substantially over-represented in sCJD patients and all confirmed vCJD cases have been MM at codon 129. ^{3Creutzfeldt-Jakob disease: A comprehensive review of current understanding and research.2024 · Journal of the neurological sciences · PMID 39546829Open reference}

Diagnostic tools include:

• MRI (DWI/FLAIR): Cortical ribboning pattern and bilateral basal ganglia or thalamic hyperintensities are highly characteristic of sCJD.

• EEG: Periodic sharp-wave complexes occur in ~60–70% of sCJD but are absent in vCJD.

• CSF biomarkers: 14-3-3 protein is elevated; total tau is markedly elevated (often >1300 pg/mL); brain-derived tau and phospho-tau ratios aid differential diagnosis from Alzheimer’s disease. ^{4Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.2024 · Alzheimer's & dementia · PMID 37858957Open reference}

• Neurofilament light chain (NfL): Blood and CSF NfL are substantially elevated in CJD compared to other dementias, reflecting rapid neuronal injury. ^{5Blood Neurofilament Light Chain in Different Types of Dementia.2023 · Current Alzheimer research · PMID 37264656Open reference}

• RT-QuIC (Real-Time Quaking-Induced Conversion): A seed amplification assay using recombinant PrP substrate that detects minute quantities of prion seeds in CSF and skin biopsy samples with >95% sensitivity and ~98% specificity. RT-QuIC has transformed ante-mortem CJD diagnosis. ^{1Prion protein amplification techniques.2018 · Handbook of clinical neurology · PMID 29887145Open reference}

Neuropathological and Cellular Mechanisms

Emerging research highlights the role of the actin cytoskeleton in CJD pathogenesis. Actin reorganization and cofilin dysregulation are observed in prion-infected neurons, and actin dynamics may influence PrP^Sc^ trafficking and accumulation, representing a potential therapeutic entry point. ^{6The Central Role of Actin in Creutzfeldt-Jakob Disease: Unlocking Therapeutic Pathways.2025 · Molecular neurobiology · PMID 40483387Open reference}

Proteinopathic crosstalk is increasingly recognized: CJD is closely linked to tau pathology (PrP^Sc^ can modulate tau phosphorylation), and comorbid Alzheimer-type and Lewy body pathology occur frequently in post-mortem CJD cases, with clinical overlap that complicates diagnosis. ^{7Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob's disease.2019 · Parkinsonism & related disorders · PMID 30777654Open reference} Neuroinflammatory mechanisms, including STING pathway activation and prion-induced innate immune signaling, are implicated in amplifying neurodegeneration. ^{8Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration.2020 · Cellular and molecular neurobiology · PMID 31584139Open reference}

Therapeutic Landscape

No disease-modifying treatment has proven effective in CJD. Quinacrine and doxycycline failed to extend survival in randomized trials. Flupirtine showed modest palliative benefit. Current investigational strategies include:

• Anti-PrP^Sc^ antibodies: Targeting misfolded PrP oligomers or surface PrP^C^ to reduce conversion substrate

• RNA interference and antisense oligonucleotides: Suppressing total PRNP expression to reduce substrate availability

• Small molecule stabilizers: Compounds that stabilize the native PrP^C^ conformation against conversion

The prion amplification assays (RT-QuIC, PMCA) developed for diagnosis are also enabling drug screening platforms, accelerating the identification of compounds that block PrP^Sc^ seeding. ^{2Differential astrocyte and oligodendrocyte vulnerability in murine Creutzfeldt-Jakob disease.2021 · Prion · PMID 34225562Open reference}0

Disease Relevance to Broader Neurodegeneration Research

CJD has been transformative for understanding protein misfolding diseases. The prion hypothesis — that pathological protein conformations propagate in a template-directed manner without nucleic acid intermediates — has profoundly influenced understanding of Alzheimer’s disease (Aβ and tau), Parkinson’s disease (α-synuclein), and ALS/FTD (TDP-43, FUS). ^{2Differential astrocyte and oligodendrocyte vulnerability in murine Creutzfeldt-Jakob disease.2021 · Prion · PMID 34225562Open reference}1 The study of prion strains (distinct conformational variants with different cell tropisms and incubation periods) has opened new frameworks for explaining clinical heterogeneity in all major neurodegenerative diseases.